Cite
MLA Citation
Richard E Clark et al.. “De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.” Lancet, vol. 4, no. 7, 2017, pp. e310–e316. http://access.bl.uk/ark:/81055/vdc_100047097750.0x000001